Repligen Co. (NASDAQ:RGEN) Position Lessened by Corebridge Financial Inc.

Corebridge Financial Inc. decreased its position in shares of Repligen Co. (NASDAQ:RGEN) by 4.3% in the fourth quarter, Holdings Channel.com reports. The firm owned 59,054 shares of the biotechnology company’s stock after selling 2,660 shares during the period. Corebridge Financial Inc.’s holdings in Repligen were worth $8,500,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RGEN. UMB Bank n.a. lifted its holdings in shares of Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 110 shares during the last quarter. Oppenheimer & Co. Inc. bought a new position in Repligen during the fourth quarter valued at approximately $216,000. Worldquant Millennium Advisors LLC lifted its stake in Repligen by 11.9% in the third quarter. Worldquant Millennium Advisors LLC now owns 50,276 shares of the biotechnology company’s stock valued at $7,482,000 after acquiring an additional 5,337 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Repligen by 1.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 363,379 shares of the biotechnology company’s stock worth $54,078,000 after acquiring an additional 5,478 shares in the last quarter. Finally, Van ECK Associates Corp increased its stake in shares of Repligen by 7.8% during the 4th quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock worth $6,078,000 after purchasing an additional 3,066 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Trading Down 1.7 %

Shares of RGEN stock opened at $137.12 on Friday. The firm has a market capitalization of $7.70 billion, a P/E ratio of -268.86, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $187.25. The firm’s fifty day simple moving average is $154.75 and its 200 day simple moving average is $148.22. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. As a group, sell-side analysts predict that Repligen Co. will post 1.72 EPS for the current year.

Insider Buying and Selling at Repligen

In other news, Director Margaret Pax acquired 250 shares of the stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on RGEN shares. Canaccord Genuity Group lifted their price objective on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. HC Wainwright reaffirmed a “buy” rating and issued a $180.00 price target on shares of Repligen in a research report on Friday, February 21st. TD Cowen started coverage on Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective on the stock. Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Finally, Evercore ISI assumed coverage on Repligen in a report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Repligen presently has an average rating of “Hold” and an average price target of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.